After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Monday, Addex Therapeutics (NASDAQ:ADXN) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson (NYSE:JNJ), has discontinued the development of ADX71149 (JNJ-40411813) in epilepsy.
週一，Addex Therapeutics（納斯達克：ADXN）宣佈其合作伙伴強生（Johnson & Johnson）子公司Janssen Pharmaceuticals，Inc停止開發ADX71149（JNJ-40411813）用於癲癇的治療。
The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 (JNJ-40411813) as an adjunctive epilepsy treatment is analyzed.
兩家公司的合作關係仍在繼續，而ADX71149(JNJ-40411813)作爲輔助癲癇治療方法的二期研究的全部數據集正在分析中。
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
決定是在四月份公佈的一期數據後作出的，該數據顯示，在僅對使用了levetiracetam或brivaracetam的患有侷限性發作的患者進行輔助治療的情況下，ADX71149添加到病人的護理標準後，未能達到病人達到基線癲癇計數所需的時間主要指標的統計學意義。
After the data, Addex Therapeutics stock tumbled almost 50%.
在數據公佈後，Addex Therapeutics的股價下跌了近50％。
"Following the Phase 2 study results in epilepsy, this decision was anticipated. We have had an excellent working relationship with Janssen for twenty years and will continue to work diligently to complete the analysis of the full Phase 2 data set to elucidate all learnings from the study," said Tim Dyer, CEO of Addex. "Once we have that information in hand, we anticipate a decision on the future of this asset."
“在癲癇二期研究結果公佈後，這個決定是可以預見的。我們與Janssen有着20年的良好工作關係，並將繼續努力完成全面的二期數據集分析，以闡明該項研究的所有學習成果，”Addex的CEO Tim Dyer說：“一旦我們掌握了這些信息，我們就會對該資產的未來做出決策。”
Price Action: ADXN stock is down 1.36% at $7.99 during the premarket session at last check Monday.
股票價格行情：截至週一早盤，ADXN股票價格爲7.99美元，下跌1.36％。
- Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications.
- 瘋狂追逐用於減肥的Ozempic和Zepbound導致糖尿病患者無法使用關鍵的GLP-1藥物。
譯文內容由第三人軟體翻譯。